Race to the finish: pharma edges closer to approval with RSV vaccines
Pharmaceutical Technology
FEBRUARY 1, 2023
As paediatric hospital wings are flooded with an unprecedented number of respiratory syncytial virus (RSV) cases , healthcare workers have been overwhelmed by an unusually early peak of the RSV season. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. per 100,000.
Let's personalize your content